When will semaglutide be generic in the US? Not before Novo Nordisk's settlements with generic makers allow it, and the company reports its US compound patent runs to 2032. Elsewhere it already is: India's patent expired on 20 March 2026, and Canada approved the first G7 generic on 28 April 2026.
Here is the argument of this piece. Almost every page answering "when will Ozempic be generic" treats the question as a patent lookup and lands on 2031 or 2032. That year is real, and it is the ceiling, not the answer. In its annual report on Form 20-F for 2025, Novo Nordisk discloses that it settled US patent litigation over Ozempic with seven generic manufacturers and that "all terms of the agreements are confidential." The date an American pharmacy could stock a generic is set by those contracts. I think the most useful number in this story is seven, not 2032, because it tells you where the answer actually lives.
Nothing below is a suggestion to buy, import or switch to any product, and nothing here is legal or medical advice. It is a report on what regulators and the patent holder have put in writing, each with a date. For the status of compounded GLP-1s, which is a separate legal route, see the compounded GLP-1 crackdown timeline, and for the regulatory status of peptides more broadly, the Ozemback peptide status tracker keeps one dated row per compound.
Where is generic semaglutide already available?
Generic semaglutide is already on sale or approved in at least two large markets, and the timing in each was set by local law rather than by the molecule. In India, the patent expired on 20 March 2026, and Dr. Reddy's Laboratories launched Obeda the next day, among the first generic injections on sale, approved by the Drugs Controller General of India and priced at Rs 4,200 a month for patients, roughly 50 dollars. Sun Pharma had announced on 23 January 2026 its own approval for a weight-management version, Noveltreat, backed by a phase 3 trial run in India. In Canada, Health Canada reported three generic approvals by 29 June 2026, with six more submissions under review. The table sets the main markets side by side.
| Market | What expired or lapsed | First generic | Status, 7 Oct 2026 |
|---|---|---|---|
| India | Patent, 20 Mar 2026 | Obeda (Dr. Reddy's), launched 21 Mar 2026 | Several brands on sale |
| Canada | Patent lapsed (unpaid fee); data protection to 4 Jan 2026 | Approved 28 Apr 2026 | 3 approved, 6 under review (29 Jun 2026) |
| China | Patent, Mar 2026 | None approved | Novo expects delay to 2027 (data protection) |
| United States | Compound patent 2032, per Novo | None approved | 7 confidential settlements |
Why did Canada get generic semaglutide before the rest of the G7?
Canada got there first because of an administrative lapse, not a policy choice. According to an October 2025 analysis by the UK patent firm Reddie & Grose, Novo Nordisk did not pay a CAD 250 maintenance fee on Canadian patent CA 2601784 in 2019, nor the late fee that would have revived it, so the patent lapsed. The certificate of supplementary protection tied to that patent, which would have run to 2028, fell with it. What remained was data protection, which ended on 4 January 2026. Health Canada then called its 28 April 2026 approval the first generic semaglutide in any G7 country. On 29 June 2026 it authorised Sevmia from Apotex, a generic of Wegovy for weight management in patients aged 12 and over.
When does the semaglutide patent expire in the US?
Novo Nordisk states it plainly in its Form 20-F for fiscal 2025: compound patent expiry in the US for Ozempic, Rybelsus and Wegovy is 2032. Third-party analyses list additional US patents on formulations, the injector pen and dosing that expire on other dates, so the compound patent is one wall among several. The same filing records that several manufacturers filed abbreviated new drug applications with Paragraph IV certifications, the mechanism a generic company uses to argue a listed patent is invalid or not infringed. Novo sued, then settled with Alvogen, Rio Biopharmaceuticals, Sun Pharma, Dr. Reddy's, Mylan, Zydus and Apotex. The filing adds that the agreements are subject to review by the Federal Trade Commission and the Department of Justice.
The US date for generic semaglutide is not printed on a patent. It is written in seven confidential settlements, and none of them is public.
What does the Victoza precedent say about the real date?
Victoza, Novo's older GLP-1 drug liraglutide, is the closest precedent, and Novo's own filing tells its story. The US compound patent for Victoza expired in 2023. Novo had settled with the generic filers, and under those settlements the manufacturers "were licensed to launch a generic version of Victoza as of June 22, 2024." Teva launched an authorised generic that month, and Hikma launched its own generic liraglutide in December 2024. The lesson is not that semaglutide will follow the same gap. The lesson is that the launch date for liraglutide came from a licence written into a settlement, and the public learned it only when the licence took effect. Semaglutide sits in the same kind of contracts, with the dates sealed.
How would the US date become public?
The US entry date for generic semaglutide will surface through records, not leaks. The FDA publishes its generic drug approvals, and when a patent or exclusivity still blocks a launch it can grant a tentative approval, which signals that an application is scientifically ready but legally parked. Novo Nordisk reports litigation and settlement changes in its annual and quarterly filings, which is where the Victoza licence date appeared. Generic companies listed on stock exchanges also disclose material launches to their investors, as Dr. Reddy's and Sun Pharma did in India. Any one of those three channels will confirm a US date before a marketing campaign does, and they are the sources this publication watches.
How much money is riding on the US date?
The scale explains why the settlements are sealed. In 2025, Novo Nordisk reported Ozempic sales of DKK 127,089 million, of which DKK 88,467 million came from US operations, about 70 percent. Wegovy added DKK 79,106 million, with DKK 51,015 million from the US, and Rybelsus DKK 22,093 million. Every month of US exclusivity on those products is worth billions of kroner, which is why a company that lost Canada over a missed CAD 250 fee guards the US timeline so carefully. Those figures also explain why generic makers settled rather than litigate to the end: a licensed date is worth more to them than an uncertain court win.
Isn't 2032 the answer, then?
The strongest counter-argument is that 2032 is the only public number and therefore the honest answer. Novo itself discloses it, and a reader planning around a date needs a date. That is fair, and 2032 is the right ceiling to quote for the compound patent. But the settlements can license entry earlier than a patent's expiry, as they routinely do in US pharmaceutical litigation, and nothing public says whether they do here. China shows the other limit: its patent expired in March 2026, yet Novo said on 6 May 2026 that it expects generics there to be delayed into 2027 because of data protection under the China-Switzerland free trade agreement. Expiry dates and launch dates are different things.
Does a generic approved in Canada or India count in the US?
No. A product approved by Health Canada or by India's drug regulator is not, by that approval, an FDA-approved drug, and marketing a new drug in the United States requires FDA approval under 21 U.S.C. 355. The Canadian and Indian launches matter for Americans in a different way: they show what price competition does once it is allowed, and they put pressure on the list price Novo charges at home. They are a signal about the market, not a route around the US approval system. When the first FDA-approved generic semaglutide arrives, it will appear in the agency's approval records and in Novo's own disclosures.
So when will semaglutide be generic in the US?
The defensible answer on 7 October 2026 is this: no FDA-approved generic exists; Novo reports a US compound patent running to 2032; seven generic makers hold settlements whose entry terms are confidential; and the Victoza precedent shows the real launch date arrives through those licences. Anyone quoting a precise earlier year is guessing or selling something. Canada and India are not a preview of the US calendar; they are proof that the molecule can be copied, approved and priced lower once the local legal barrier falls. The letter will report the first FDA approval or disclosed licence date when it happens, dated and sourced.
Ozemback, October 2026
Sources
- Novo Nordisk A/S, Form 20-F for fiscal year 2025 (patent expiry, Paragraph IV litigation and settlements, 2025 product sales), SEC EDGAR. www.sec.gov
- Health Canada, Canada approves first generic semaglutide for weight loss, 29 June 2026. www.canada.ca
- Apotex, first Canadian-based company to receive Health Canada approval for a generic equivalent of Ozempic, 1 May 2026. www.apotex.com
- Reddie & Grose, A key Ozempic patent lapses in Canada: deliberate or a mistake?, 15 October 2025. www.reddie.co.uk
- Sun Pharma, DCGI approval for generic semaglutide injection for chronic weight management, 23 January 2026. sunpharma.com
- BioSpectrum India, Dr. Reddy's announces launch of DCGI-approved semaglutide injection Obeda, March 2026. biospectrumindia.com
- Malay Mail, India set to roll out cheap weight-loss jabs as patent expires, 20 March 2026. www.malaymail.com
- Swissinfo, Novo sees generic Ozempic delayed in China until next year, 6 May 2026. www.swissinfo.ch
- 21 U.S.C. 355, new drugs (FDA approval requirement). www.law.cornell.edu
